{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T12:52:15Z","timestamp":1791636735173,"version":"4.3.4"},"reference-count":61,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T00:00:00Z","timestamp":1789948800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Chromatography A"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1016\/j.chroma.2026.467472","type":"journal-article","created":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T15:59:17Z","timestamp":1790006357000},"page":"467472","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["From screen to selectivity: bespoke liquid chromatography strategies for separating siRNA phosphorothioate diastereomers across diverse sequences and conjugates"],"prefix":"10.1016","volume":"1788","author":[{"ORCID":"https:\/\/orcid.org\/0009-0002-7656-9191","authenticated-orcid":false,"given":"Lucy C","family":"Durham","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joanna M","family":"Hemming","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edward TF","family":"Ahearne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anish","family":"Doshi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.chroma.2026.467472_bib0001","doi-asserted-by":"crossref","first-page":"2529","DOI":"10.1093\/nar\/gkad067","article-title":"Chemistry, structure and function of approved oligonucleotide therapeutics","volume":"51","author":"Egli","year":"2023","journal-title":"Nucleic. Acids. Res."},{"issue":"10","key":"10.1016\/j.chroma.2026.467472_bib0002","doi-asserted-by":"crossref","first-page":"1733","DOI":"10.1016\/j.drudis.2018.05.030","article-title":"Drug metabolism and pharmacokinetic strategies for oligonucleotide- and mRNA-based drug development","volume":"23","author":"Andersson","year":"2018","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.chroma.2026.467472_bib0003","first-page":"1","article-title":"Chapter 1","author":"Agrawal","year":"2019","journal-title":"Hist. Dev. Nucleotide Analog. Nucleic Acids Drugs"},{"issue":"3","key":"10.1016\/j.chroma.2026.467472_bib0004","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1172\/JCI125228","article-title":"Selective tissue targeting of synthetic nucleic acid drugs","volume":"129","author":"Seth","year":"2019","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.chroma.2026.467472_bib0005","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1146\/annurev-pharmtox-010818-021050","article-title":"Therapeutic oligonucleotides: state of the art","volume":"59","author":"Smith","year":"2019","journal-title":"Annu. Rev. Pharmacol. Toxicol."},{"issue":"2","key":"10.1016\/j.chroma.2026.467472_bib0006","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1111\/cts.12624","article-title":"Targeting RNA: a transformative therapeutic strategy","volume":"12","author":"Yin","year":"2019","journal-title":"Clin. Transl. Sci."},{"issue":"3","key":"10.1016\/j.chroma.2026.467472_bib0007","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1021\/acsmedchemlett.9b00582","article-title":"New chemical modalities and strategic thinking in early drug discovery","volume":"11","author":"Blanco","year":"2020","journal-title":"ACS. Med. Chem. Lett."},{"key":"10.1016\/j.chroma.2026.467472_bib0008","article-title":"New therapeutic modalities for rare diseases","volume":"7","author":"Ezgu","year":"2024","journal-title":"Glob. Pediatr."},{"issue":"35","key":"10.1016\/j.chroma.2026.467472_bib0009","doi-asserted-by":"crossref","first-page":"10294","DOI":"10.1002\/anie.201611914","article-title":"New modalities for challenging targets in drug discovery","volume":"56","author":"Valeur","year":"2017","journal-title":"Angew. Chem. Int. Engl."},{"issue":"4","key":"10.1016\/j.chroma.2026.467472_bib0010","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.3390\/pharmaceutics15041130","article-title":"Enhancing the effectiveness of oligonucleotide therapeutics using cell-penetrating peptide conjugation, chemical modification, and carrier-based delivery strategies","volume":"15","author":"Anwar","year":"2023","journal-title":"Pharmaceutics"},{"issue":"8","key":"10.1016\/j.chroma.2026.467472_bib0011","first-page":"909","article-title":"The Medicinal chemistry of artificial nucleic acids and therapeutic oligonucleotides","volume":"15","author":"Bege","year":"2022","journal-title":"Pharm. (Basel)"},{"issue":"2","key":"10.1016\/j.chroma.2026.467472_bib0012","doi-asserted-by":"crossref","first-page":"260","DOI":"10.3390\/pharmaceutics14020260","article-title":"Oligonucleotide therapeutics: from discovery and development to patentability","volume":"14","author":"Moumn\u00e9","year":"2022","journal-title":"Pharmaceutics"},{"issue":"21","key":"10.1016\/j.chroma.2026.467472_bib0013","doi-asserted-by":"crossref","first-page":"9645","DOI":"10.1021\/acs.jmedchem.6b00551","article-title":"The medicinal chemistry of therapeutic oligonucleotides","volume":"59","author":"Wan","year":"2016","journal-title":"J. Med. Chem."},{"issue":"1","key":"10.1016\/j.chroma.2026.467472_bib0014","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1038\/s41392-020-0207-x","article-title":"Therapeutic siRNA: state of the art","volume":"5","author":"Hu","year":"2020","journal-title":"Signal Transduct. Target. Ther."},{"issue":"18","key":"10.1016\/j.chroma.2026.467472_bib0015","doi-asserted-by":"crossref","first-page":"1729","DOI":"10.1007\/s40265-023-01976-4","article-title":"Nedosiran: first approval","volume":"83","author":"Syed","year":"2023","journal-title":"Drugs"},{"issue":"11","key":"10.1016\/j.chroma.2026.467472_bib0016","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1038\/s41573-025-01237-x","article-title":"RNA chemistry and therapeutics","volume":"24","author":"Wang","year":"2025","journal-title":"Nat. Rev. Drug Discov."},{"issue":"6\u20137","key":"10.1016\/j.chroma.2026.467472_bib0017","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1080\/07328319908044659","article-title":"Diastereomeric process control in the synthesis of oligodeoxyribonucleotide phosphorothioates","volume":"18","author":"Cheruvallath","year":"1999","journal-title":"Nucleosides. Nucleotides."},{"issue":"1","key":"10.1016\/j.chroma.2026.467472_bib0018","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1006\/bioo.1995.1003","article-title":"Stereo-reproducibility of the phosphoramidite method in the synthesis of oligonucleotide phosphorothioates","volume":"23","author":"Wyrzykiewicz","year":"1995","journal-title":"Bioorg. Chem."},{"issue":"6","key":"10.1016\/j.chroma.2026.467472_bib0019","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1021\/op020061c","article-title":"Development of 2\u2018-O-methoxyethyl phosphorothioate oligonucleotides as antisense drugs under stereochemical control","volume":"6","author":"Ravikumar","year":"2002","journal-title":"Org. Process. Res. Dev."},{"issue":"5\u20138","key":"10.1016\/j.chroma.2026.467472_bib0020","doi-asserted-by":"crossref","first-page":"1639","DOI":"10.1081\/NCN-120023089","article-title":"Diastereomeric process control in the synthesis of 2\u2032-O-(2-Methoxyethyl) oligoribonucleotide phosphorothioates as antisense drugs","volume":"22","author":"Ravikumar","year":"2003","journal-title":"Nucleosides. Nucleotides. Nucleic. Acids."},{"issue":"1","key":"10.1016\/j.chroma.2026.467472_bib0021","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1021\/acs.oprd.4c00382","article-title":"Overview and recent advances in the purification and isolation of therapeutic oligonucleotides","volume":"29","author":"Abe","year":"2025","journal-title":"Org. Process. Res. Dev."},{"issue":"4","key":"10.1016\/j.chroma.2026.467472_bib0022","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1089\/nat.2021.0089","article-title":"Inhomogeneous diastereomeric composition of Mongersen antisense phosphorothioate oligonucleotide preparations and related pharmacological activity impairment","volume":"32","author":"Arrico","year":"2022","journal-title":"Nucleic. Acid. Ther."},{"issue":"35","key":"10.1016\/j.chroma.2026.467472_bib0023","doi-asserted-by":"crossref","first-page":"14754","DOI":"10.1021\/jacs.0c04928","article-title":"The interaction of phosphorothioate-containing RNA targeted drugs with proteins is a critical determinant of the therapeutic effects of these agents","volume":"142","author":"Crooke","year":"2020","journal-title":"J. Am. Chem. Soc."},{"issue":"10","key":"10.1016\/j.chroma.2026.467472_bib0024","doi-asserted-by":"crossref","first-page":"4713","DOI":"10.1093\/nar\/gkad309","article-title":"Controlled sulfur-based engineering confers mouldability to phosphorothioate antisense oligonucleotides","volume":"51","author":"Genna","year":"2023","journal-title":"Nucleic Acids Res."},{"issue":"9","key":"10.1016\/j.chroma.2026.467472_bib0025","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1038\/nbt.3948","article-title":"Control of phosphorothioate stereochemistry substantially increases the efficacy of antisense oligonucleotides","volume":"35","author":"Iwamoto","year":"2017","journal-title":"Nat. Biotechnol."},{"issue":"1","key":"10.1016\/j.chroma.2026.467472_bib0026","doi-asserted-by":"crossref","first-page":"6317","DOI":"10.1038\/ncomms7317","article-title":"Stereochemical bias introduced during RNA synthesis modulates the activity of phosphorothioate siRNAs","volume":"6","author":"Jahns","year":"2015","journal-title":"Nat. Commun."},{"issue":"3","key":"10.1016\/j.chroma.2026.467472_bib0027","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1093\/nar\/gkab544","article-title":"Chirality matters: stereo-defined phosphorothioate linkages at the termini of small interfering RNAs improve pharmacology in vivo","volume":"50","author":"Jahns","year":"2022","journal-title":"Nucleic Acids Res."},{"issue":"10","key":"10.1016\/j.chroma.2026.467472_bib0028","doi-asserted-by":"crossref","first-page":"5443","DOI":"10.1093\/nar\/gkac018","article-title":"Control of backbone chemistry and chirality boost oligonucleotide splice switching activity","volume":"50","author":"Kandasamy","year":"2022","journal-title":"Nucleic Acids Res."},{"issue":"6","key":"10.1016\/j.chroma.2026.467472_bib0029","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1089\/154545703322860807","article-title":"P-chirality-dependent immune activation by phosphorothioate CpG oligodeoxynucleotides","volume":"13","author":"Krieg","year":"2003","journal-title":"Oligonucleotides"},{"issue":"1","key":"10.1016\/j.chroma.2026.467472_bib0030","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1089\/nat.2020.0906","article-title":"Stereocontrolled oligonucleotides for Nucleic acid therapeutics: a perspective","volume":"31","author":"Meena","year":"2021","journal-title":"Nucleic. Acid. Ther."},{"issue":"4","key":"10.1016\/j.chroma.2026.467472_bib0031","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1093\/nar\/gkaa031","article-title":"Understanding the effect of controlling phosphorothioate chirality in the DNA gap on the potency and safety of gapmer antisense oligonucleotides","volume":"48","author":"\u00d8stergaard","year":"2020","journal-title":"Nucleic. Acids. Res."},{"issue":"1","key":"10.1016\/j.chroma.2026.467472_bib0032","doi-asserted-by":"crossref","first-page":"95","DOI":"10.3390\/pharmaceutics15010095","article-title":"Smad7 Antisense oligonucleotide in Crohn\u2019s Disease: a re-evaluation and explanation for the discordant results of clinical trials","volume":"15","author":"Monteleone","year":"2023","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.chroma.2026.467472_bib0033","author":"Agency"},{"key":"10.1016\/j.chroma.2026.467472_bib0034","doi-asserted-by":"crossref","DOI":"10.1016\/j.chroma.2025.466308","article-title":"Emerging trends in the characterization of oligonucleotide diastereomers","volume":"1761","author":"Goyon","year":"2025","journal-title":"J. Chromatogr. A"},{"issue":"12","key":"10.1016\/j.chroma.2026.467472_bib0035","doi-asserted-by":"crossref","first-page":"4194","DOI":"10.1021\/acs.oprd.4c00380","article-title":"Why and how to control P-chirality in phosphorothioated therapeutic oligonucleotides: analytical challenges associated with determination of stereochemical composition","volume":"28","author":"Poredo\u0161","year":"2024","journal-title":"Org. Process. Res. Dev."},{"key":"10.1016\/j.chroma.2026.467472_bib0036","doi-asserted-by":"crossref","DOI":"10.1016\/j.chroma.2025.466550","article-title":"Current trends in liquid chromatography-mass spectrometry analysis of small interfering RNAs: a short review","volume":"1766","author":"Togawa","year":"2026","journal-title":"J. Chromatogr. A"},{"key":"10.1016\/j.chroma.2026.467472_bib0037","doi-asserted-by":"crossref","DOI":"10.1016\/j.chroma.2020.461653","article-title":"Impact of stationary-phase pore size on chromatographic performance using oligonucleotide separation as a model","volume":"1634","author":"Bagge","year":"2020","journal-title":"J. Chromatogr. A"},{"issue":"28","key":"10.1016\/j.chroma.2026.467472_bib0038","doi-asserted-by":"crossref","first-page":"6313","DOI":"10.1007\/s00216-025-06123-4","article-title":"Separation of PS diastereomers in GalNAc-conjugated siRNA-a comparative study of chromatographic and ion mobility mass spectrometry approaches","volume":"417","author":"Bill","year":"2025","journal-title":"Anal. Bioanal. Chem."},{"key":"10.1016\/j.chroma.2026.467472_bib0039","doi-asserted-by":"crossref","DOI":"10.1016\/j.chroma.2025.466639","article-title":"Decoding diastereomeric and impurity profiles of phosphorothioated siRNAs via 2D anion-exchange chromatography coupled with ion-pair reversed phase liquid chromatography mass spectrometry","volume":"1768","author":"Bui","year":"2026","journal-title":"J. Chromatogr. A"},{"issue":"7\u20138","key":"10.1016\/j.chroma.2026.467472_bib0040","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1002\/ansa.202000175","article-title":"Evaluation of micropillar array columns for chromatographic separation of phosphorothioated oligonucleotides and their diastereomers","volume":"2","author":"Dillen","year":"2021","journal-title":"Anal. Sci. Adv."},{"issue":"2","key":"10.1016\/j.chroma.2026.467472_bib0041","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1007\/s00216-019-02236-9","article-title":"Analytical and preparative separation of phosphorothioated oligonucleotides: columns and ion-pair reagents","volume":"412","author":"Enmark","year":"2020","journal-title":"Anal. Bioanal. Chem."},{"issue":"15","key":"10.1016\/j.chroma.2026.467472_bib0042","doi-asserted-by":"crossref","first-page":"3383","DOI":"10.1007\/s00216-019-01813-2","article-title":"Investigation of factors influencing the separation of diastereomers of phosphorothioated oligonucleotides","volume":"411","author":"Enmark","year":"2019","journal-title":"Anal. Bioanal. Chem."},{"key":"10.1016\/j.chroma.2026.467472_bib0043","doi-asserted-by":"crossref","DOI":"10.1016\/j.chroma.2022.463201","article-title":"Phosphorothioate oligonucleotides separation in ion-pairing reversed-phase liquid chromatography: effect of ion-pairing system","volume":"1676","author":"Kadlecova","year":"2022","journal-title":"J. Chromatogr. A"},{"key":"10.1016\/j.chroma.2026.467472_bib0044","doi-asserted-by":"crossref","DOI":"10.1016\/j.chroma.2024.465076","article-title":"Two-dimensional sequential selective comprehensive chiralxreversed-phase liquid chromatography of synthetic phosphorothioate oligonucleotide diastereomers","volume":"1730","author":"Li","year":"2024","journal-title":"J. Chromatogr. A"},{"key":"10.1016\/j.chroma.2026.467472_bib0045","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.chroma.2017.04.008","article-title":"Separation of small interfering RNA stereoisomers using reversed-phase ion-pairing chromatography","volume":"1500","author":"Li","year":"2017","journal-title":"J. Chromatogr. A"},{"issue":"6","key":"10.1016\/j.chroma.2026.467472_bib0046","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1016\/j.chroma.2010.12.051","article-title":"Separation of oligonucleotide phosphorothioate diastereoisomers by pellicular anion-exchange chromatography","volume":"1218","author":"Thayer","year":"2011","journal-title":"J. Chromatogr. A"},{"key":"10.1016\/j.chroma.2026.467472_bib0047","doi-asserted-by":"crossref","DOI":"10.1016\/j.chroma.2024.464847","article-title":"Separation of the diastereomers of phosphorothioated siRNAs by anion-exchange chromatography under non-denaturing conditions","volume":"1721","author":"Togawa","year":"2024","journal-title":"J. Chromatogr. A"},{"key":"10.1016\/j.chroma.2026.467472_bib0048","doi-asserted-by":"crossref","DOI":"10.1016\/j.chroma.2024.465285","article-title":"Impact of mobile and stationary phases on siRNA duplex stability in liquid chromatography","volume":"1733","author":"Gilar","year":"2024","journal-title":"J. Chromatogr. A"},{"issue":"24","key":"10.1016\/j.chroma.2026.467472_bib0049","doi-asserted-by":"crossref","first-page":"9994","DOI":"10.1021\/acs.analchem.4c01384","article-title":"Unravelling the link between oligonucleotide structure and diastereomer separation in hydrophilic interaction chromatography","volume":"96","author":"Lardeux","year":"2024","journal-title":"Anal. Chem."},{"key":"10.1016\/j.chroma.2026.467472_bib0050","doi-asserted-by":"crossref","DOI":"10.1016\/j.chroma.2026.467137","article-title":"Diastereomer separation of phosphorothioate oligonucleotides via conformationally stabilizing ion pairs in reversed-phase liquid chromatography","volume":"1783","author":"Zhang","year":"2026","journal-title":"J. Chromatogr. A"},{"key":"10.1016\/j.chroma.2026.467472_bib0051","doi-asserted-by":"crossref","DOI":"10.1016\/j.chroma.2024.465074","article-title":"Impact of ion-pairing systems choice on diastereomeric selectivity of phosphorothioated oligonucleotides in reversed-phase liquid chromatography","volume":"1730","author":"Vosahlova","year":"2024","journal-title":"J. Chromatogr. A"},{"issue":"47","key":"10.1016\/j.chroma.2026.467472_bib0052","doi-asserted-by":"crossref","first-page":"18590","DOI":"10.1021\/acs.analchem.4c05248","article-title":"Expanding the analytical toolbox for the nondenaturing analysis of siRNAs with salt-mediated ion-pair reversed-phase liquid chromatography","volume":"96","author":"Enmark","year":"2024","journal-title":"Anal. Chem."},{"key":"10.1016\/j.chroma.2026.467472_bib0053","doi-asserted-by":"crossref","DOI":"10.1016\/j.chroma.2022.463349","article-title":"Analytical techniques for characterizing diastereomers of phosphorothioated oligonucleotides","volume":"1678","author":"Chen","year":"2022","journal-title":"J. Chromatogr. A"},{"issue":"2","key":"10.1016\/j.chroma.2026.467472_bib0054","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/0014-5793(91)80707-A","article-title":"The Hofmeister series and ionic strength","volume":"284","author":"Leberman","year":"1991","journal-title":"FEBS Lett."},{"issue":"6","key":"10.1016\/j.chroma.2026.467472_bib0055","doi-asserted-by":"crossref","DOI":"10.1098\/rsfs.2017.0030","article-title":"Factors affecting the physical stability (aggregation) of peptide therapeutics","volume":"7","author":"Zapadka","year":"2017","journal-title":"Interface Focus."},{"issue":"12","key":"10.1016\/j.chroma.2026.467472_bib0056","doi-asserted-by":"crossref","first-page":"3605","DOI":"10.1039\/D1NA00216C","article-title":"From nanoaggregates to mesoscale ribbons: the multistep self-organization of amphiphilic peptides","volume":"3","author":"Messina","year":"2021","journal-title":"Nanoscale Adv."},{"issue":"39","key":"10.1016\/j.chroma.2026.467472_bib0057","doi-asserted-by":"crossref","first-page":"11537","DOI":"10.1021\/jp5031569","article-title":"Effects of salt concentrations of the aqueous peptide-amphiphile solutions on the sol\u2013Gel transitions, the gelation speed, and the gel characteristics","volume":"118","author":"Otsuka","year":"2014","journal-title":"J. Phys. Chem. B"},{"key":"10.1016\/j.chroma.2026.467472_bib0058","doi-asserted-by":"crossref","DOI":"10.1016\/j.chroma.2024.465314","article-title":"Probing the higher order structure of oligonucleotides through anion exchange chromatography","volume":"1734","author":"Wei","year":"2024","journal-title":"J. Chromatogr. A"},{"issue":"5","key":"10.1016\/j.chroma.2026.467472_bib0059","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1021\/cr60273a002","article-title":"Sites and thermodynamic quantities associated with proton and metal ion interaction with ribonucleic acid, deoxyribonucleic acid, and their constituent bases, nucleosides, and nucleotides","volume":"71","author":"Izatt","year":"1971","journal-title":"Chem. Rev."},{"issue":"1\u20132","key":"10.1016\/j.chroma.2026.467472_bib0060","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.chroma.2007.09.005","article-title":"Peak capacity in gradient reversed-phase liquid chromatography of biopolymers. Theoretical and practical implications for the separation of oligonucleotides","volume":"1169","author":"Gilar","year":"2007","journal-title":"J. Chromatogr. A"},{"key":"10.1016\/j.chroma.2026.467472_bib0061","article-title":"Effect of pore size on plate height for 23-mer oligonucleotides separated using fully porous particles and ion-pairing reversed-phase liquid chromatography","author":"Stoll","year":"2026","journal-title":"SSRN [Preprint]"}],"container-title":["Journal of Chromatography A"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0021967326007983?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0021967326007983?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T12:06:16Z","timestamp":1791633976000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0021967326007983"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,11]]},"references-count":61,"alternative-id":["S0021967326007983"],"URL":"https:\/\/doi.org\/10.1016\/j.chroma.2026.467472","relation":{},"ISSN":["0021-9673"],"issn-type":[{"value":"0021-9673","type":"print"}],"subject":[],"published":{"date-parts":[[2026,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"From screen to selectivity: bespoke liquid chromatography strategies for separating siRNA phosphorothioate diastereomers across diverse sequences and conjugates","name":"articletitle","label":"Article Title"},{"value":"Journal of Chromatography A","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.chroma.2026.467472","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"467472"}}